Research

Hormonal

Subcutaneous administration of a semaglutide-rosuvastatin-lipid conjugate nanoparticle (SRLC NP) formulation significantly reduces body weight and improves liver function markers in high-fat diet-induced obese mice compared to conventional semaglutide or individual components.

This research describes a novel experimental nanoparticle formulation combining semaglutide with a statin-lipid conjugate. In obese mice, this specific formulation led to significant weight loss and liver health improvements compared to standard treatments. However, this is preclinical data; it is not a current treatment option for humans, and the safety and efficacy in people remain unproven.

ModerateSupportsMEDIUM confidence
In animal experiments, the treatment group demonstrated a 30.24% reduction in body weight and a 46.80% improvement in liver function markers compared to the control group.
Kyeong-Ju Lee et al. · Pharmaceutics · 2025

Why this rating

The evidence is from an animal model (mice) using a novel, unapproved nanotherapeutic formulation; results are promising but not yet validated in human clinical trials.

Source

Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin–Lipid Conjugate-Based Nanoparticle

Kyeong-Ju Lee et al. · Pharmaceutics · 2025

DOI 10.3390/pharmaceutics17040480

mechanism_only · n=25Cited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →